Invivogen
Menu

Anti-EGFR (Cetuximab biosimilar - IgG1 isotype)

Anti-hEGFR-hIgG1 Unit size Cat. code Docs Qty Price
Human EGFR (Cetuximab) antibody - Human IgG1
100 µg
hegfr-mab1
+-
$372.00

You may also need : Anti-β-Gal-hIgG1 | View more associated products

Human IgG1 monoclonal antibody (mAb) against human EGFR

Anti-hEGFR-hIgG1 features the constant region of the human IgG1 isotype and the variable region of cetuximab. Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets epidermal growth factor receptor (EGFR), a cell surface receptor overexpressed in many types of cancer.

EGFR is activated by binding specific ligands, including epidermal growth factor and transforming growth factor-α. Activation of EGFR promotes cell proliferation and survival, as well as angiogenesis, leading to tumor growth and metastasis.

Binding of cetuximab to EGFR blocks ligand/receptor binding and induces receptor internalization and subsequent degradation.

Consequently, cetuximab blocks downstream pathways which regulate cell growth and angiogenesis. In addition, cetuximab induces cell death through antibody-dependent cell-mediated cytotoxicity (ADCC) [1, 2]. Cetuximab has been approved by the FDA for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck [3].

Anti-hEGFR-hIgG1 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

 

References:

Kurai J. et al., 2007. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 3(5):1552-61.
Kimura H. et al., 2007. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98(8):1275-80.
Vincenzi B. et al., 2010. Cetuximab: from bench to bedside. Curr Cancer Drug Targets. 10(1):80-95.

Figures

Comparison of ADCC potency for native and engineered anti-human EGFR antibody isotypes
Comparison of ADCC potency for native and engineered anti-human EGFR antibody isotypes

Comparison of ADCC potency for native and engineered anti-human EGFR antibody isotypes. Raji-hEGFR cells were incubated with gradient concentrations of Anti-hEGFR or Anti-β-galactosidase (β-Gal) mAbs for 1 hour. Jurkat-Lucia™ NFAT-CD16 effector cells were then co-incubated with target cells for 6 hours. NFAT activation, reflecting the induced ADCC response, was assessed by determining Lucia luciferase activity in the supernatant using QUANTI-Luc™. Percentages of the maximal response normalized to the IgG1 isotype are shown.

Back to the top

Specifications

Specificity: Targets cells expressing human EGFR

Clonality: Monoclonal antibody

Isotype: Human IgG1, kappa

Source: CHO cells

Purity: Purified by affinity chromatography with protein G

Quality control:

  • Binding of Anti-hEGFR-hIgG1 to human EGFR has been tested using flow cytometry.
  • The complete sequence of this antibody has been verified.
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.
Back to the top

Contents

  • 100 µg purified anti-hEGFR-hIgG1 antibody, provided azide-free and lyophilized

room temperature Product is shipped at room temperature

store Store lyophilized antibody at -20°

stability lyophilized product is table for 1 year

Back to the top

Citations

Customer Service
& Technical Support
Shopping cart is empty